# Arbutus Biopharma Corp (ABUS)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/arbutus-biopharma-corp/ JSON: https://steadybase.io/company/arbutus-biopharma-corp.json Checked Nov 10, 2026. Latest filing read: Aug 24, 2026.

## Company

- Legal name: Arbutus Biopharma Corp
- Ticker: ABUS (Nasdaq)
- SEC CIK: 0001447028
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Warminster, PA
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company
- Website: arbutusbio.com
- LinkedIn: https://www.linkedin.com/company/arbutus-biopharma-corporation
- Next earnings date: Nov 12, 2026

## Key facts

- Revenue: $14.1M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 23, 2026). Source: https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/0001447028-26-000017-index.html
- Operating income: -$38.2M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 23, 2026). Source: https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/0001447028-26-000017-index.html
- Net income: -$33.5M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 23, 2026). Source: https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/0001447028-26-000017-index.html
- SG&A: $15.9M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 23, 2026). Source: https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/0001447028-26-000017-index.html
- Employees: 19 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/abus-20251231.htm
- Shares outstanding: 197,847,835 as of Aug 10, 2026 (10-Q filed Aug 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1447028/000144702826000045/0001447028-26-000045-index.html
- Auditor: Ernst & Young LLP, Philadelphia, Pennsylvania, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/abus-20251231.htm

## Business

Arbutus Biopharma Corporation (“Arbutus”, the “Company”, “we”, “us”, and “our”) is a clinical-stage biopharmaceutical company focused on infectious disease. We are currently developing imdusiran (AB-729), our proprietary, GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, our proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV).

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/abus-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $14.1M | -$38.2M | -$33.5M | $15.9M |
| Dec 31, 2024 | $6.2M | -$76.3M | -$69.9M | $22.1M |
| Dec 31, 2023 | $18.1M | -$78.1M | -$72.8M | $22.5M |
| Dec 31, 2022 | $39.0M | -$65.5M | -$69.5M | $17.8M |
| Dec 31, 2021 | $11.0M | -$73.5M | -$76.2M | $17.1M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/arbutus-biopharma-corp.json

## Officers and directors

- Lindsay Androski, President and CEO. LinkedIn: https://linkedin.com/in/lindsayandroski. Source: Form 4 filed Sep 23, 2026, https://www.sec.gov/Archives/edgar/data/1447028/000144702826000053/0001447028-26-000053-index.htm
- Tuan Nguyen, Chief Financial Officer. Source: Form 4 filed Sep 23, 2026, https://www.sec.gov/Archives/edgar/data/1447028/000144702826000052/0001447028-26-000052-index.htm
- Anuj Hasija, our Board. Source: 10-K filed Mar 23, 2026, https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/abus-20251231.htm
- Joseph Bishop, Board member (per proxy). Source: DEF 14A filed Apr 14, 2026, https://www.sec.gov/Archives/edgar/data/1447028/000114036126014623/ny20065142x1_def14a.htm
- Matthew Gline, Board member (per proxy). Source: DEF 14A filed Apr 14, 2026, https://www.sec.gov/Archives/edgar/data/1447028/000114036126014623/ny20065142x1_def14a.htm
- Robert Alan Beardsley, Board member (per proxy). Source: DEF 14A filed Apr 14, 2026, https://www.sec.gov/Archives/edgar/data/1447028/000114036126014623/ny20065142x1_def14a.htm
- Roger Sawhney, Board member (per proxy). Source: DEF 14A filed Apr 14, 2026, https://www.sec.gov/Archives/edgar/data/1447028/000114036126014623/ny20065142x1_def14a.htm

## Recent 8-K events

- Oct 22, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1447028/000117184326006753/f8k_102126.htm
- Aug 21, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1447028/000110465926099390/tm2623751d1_8k.htm
- Aug 12, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1447028/000117184326005442/f8k_081226.htm
- Jul 16, 2026: Item 1.02, Termination of a material definitive agreement; Item 5.02, Departure or appointment of directors or officers; compensation; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1447028/000117184326004708/f8k_071626.htm
- May 27, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1447028/000144702826000024/abus-20260526.htm
- May 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1447028/000117184326003346/f8k_051226.htm
- Apr 15, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1447028/000117184326002458/f8k_041426.htm
- Mar 23, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1447028/000117184326001838/f8k_032026.htm
- Mar 3, 2026: Item 1.01, Entry into a material definitive agreement; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/f8k_030326.htm
- Feb 20, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1447028/000117184326000979/f8k_021926.htm

## What management said

- "This has been an exciting quarter for our imdusiran development program" Lindsay Androski, President and CEO of Arbutus (8-K filed Aug 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1447028/000117184326005442/exh_991.htm

## Latest filings

- 8-K filed Oct 22, 2026: https://www.sec.gov/Archives/edgar/data/1447028/000117184326006753/f8k_102126.htm
- 10-K filed Mar 23, 2026: https://www.sec.gov/Archives/edgar/data/1447028/000144702826000017/abus-20251231.htm
- 10-Q filed Aug 12, 2026: https://www.sec.gov/Archives/edgar/data/1447028/000144702826000045/abus-20260630.htm
- 20f filed Mar 27, 2013: https://www.sec.gov/Archives/edgar/data/1447028/000119312513129590/d508557d20f.htm
- DEF 14A filed Apr 14, 2026: https://www.sec.gov/Archives/edgar/data/1447028/000114036126014623/ny20065142x1_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/